Analysts at Jefferies Financial Group began coverage on shares of Liquidia Technologies (NASDAQ:LQDA) in a research note issued to investors on Thursday, Marketbeat reports. The brokerage set a “buy” rating and a $27.00 price target on the stock. Jefferies Financial Group’s target price suggests a potential upside of 41.51% from the stock’s current price.
LQDA has been the topic of a number of other research reports. Needham & Company LLC began coverage on shares of Liquidia Technologies in a research report on Monday, August 20th. They issued a “buy” rating and a $30.00 price objective on the stock. Cowen set a $40.00 target price on shares of Liquidia Technologies and gave the stock a “buy” rating in a research report on Wednesday, October 31st. Wedbush initiated coverage on shares of Liquidia Technologies in a research report on Tuesday, September 4th. They set an “outperform” rating and a $26.00 target price on the stock. Finally, Zacks Investment Research downgraded shares of Liquidia Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Liquidia Technologies has a consensus rating of “Buy” and an average price target of $31.75.
Shares of Liquidia Technologies stock traded up $0.85 on Thursday, reaching $19.08. The stock had a trading volume of 24,759 shares, compared to its average volume of 52,688. The company has a quick ratio of 6.27, a current ratio of 6.27 and a debt-to-equity ratio of 0.40. Liquidia Technologies has a 1 year low of $10.52 and a 1 year high of $38.46.
A number of large investors have recently added to or reduced their stakes in the business. FMR LLC purchased a new stake in Liquidia Technologies during the 3rd quarter worth approximately $6,729,000. BlackRock Inc. purchased a new stake in Liquidia Technologies during the 3rd quarter worth approximately $5,924,000. Finally, Dean Capital Investments Management LLC purchased a new stake in Liquidia Technologies during the 3rd quarter worth approximately $1,483,000. 0.01% of the stock is currently owned by institutional investors.
About Liquidia Technologies
Liquidia Technologies, Inc is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies.
Recommended Story: Buyback For Investors Defined
Receive News & Ratings for Liquidia Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Technologies and related companies with MarketBeat.com's FREE daily email newsletter.